Cianna debuts ScoutCare program

Brachytherapy firm Cianna Medical is launching its ScoutCare support program...Read more on AuntMinnie.comRelated Reading: Cianna touts Scout research Cianna nets FDA OK for radar system Cianna highlights SAVI Scout results at SBI Cianna advances 2 SAVI Scout studies Cianna nets FDA OK for SAVI Scout
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended d...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
AbstractBackgroundThe aim of this work was to confirm that post-selective internal radiation therapy (SIRT)90Y-PET/CT-based dosimetry correlates with lesion metabolic response and to determine its correlation with overall survival (OS) in liver-only metastases from colorectal cancer (mCRC) patients treated with SIRT. Twenty-four mCRC patients underwent pre/post-SIRT FDG-PET/CT and post-SIRT90Y-PET/CT. Lesions delineated on pre/post-SIRT FDG-PET/CT were classified as non-metabolic responders (total lesion glycolysis (TLG)-decrease Dmean-under-treated) and in the “under-treated” group (at least one lesion receive...
Source: EJNMMI Research - Category: Radiology Source Type: research
This study compared five nomograms to clinical data from dynamic modified-peripheral intraoperative PSI to determine (a) the cause of excess seeds and (b) the optimal nomogram for our institution. Pre- and intraoperative patient data were collected for monotherapy PSIs and compiled into a clinical database. All patients were prescribed 125 Gy with dose coverage of D90% = 100% to the planning target volume (PTV) using 103 Pd seeds with mean air-kerma strength (SK¯) of 2 U. Seeds were ordered based upon an in-house nomogram as a function of preoperative prostate volume and prescription dose. Preopera...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
CONCLUSIONS: The 2D in vivo rectal dosimetry using the ERB with EBT3 films was effective and might be clinically applicable for HDR brachytherapy for cervical and prostate cancers to monitor treatment accuracy and consistency as well as to predict rectal toxicity. PMID: 30004264 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusion: There may be a role for GEP assessment in high-risk, indeterminate, posteriorly located choroidal lesions to assist in treatment planning.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
Conclusion: In spite of the rapid development of external beam radiation therapy brachytherapy continues to remain an important mode of therapy and is often a default treatment when external beam radiation option is limited.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Medical isotope developer IsoRay has received 510(k) clearance from the U.S....Read more on AuntMinnie.comRelated Reading: IsoRay revenues climb in Q4 IsoRay highlights cesium-131 brachytherapy research IsoRay touts prostate cancer treatment data FDA responds to IsoRay's GammaTile 510(k) Court approves IsoRay class-action settlement
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
IsoRay (NYSE:ISR) has inked a private placement deal worth approximately $8.3 million, according to an SEC filing posted this week. Through the deal, Richland, Wash.-based IsoRay is floating 11 million shares of common stock at 75¢ per share with several institutional and accredited investors, according to the filing. The company said it will also offer unregistered warrants to purchase a number of shares equal to 50% of the investors shares at an exercise price of 75¢, exercisable six months after issuance out to 5.5 years, according to an SEC filing. A total of 5.5 million shares will be offered through th...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Wall Street Beat IsoRay Source Type: news
Publication date: July 2018Source: European Urology Supplements, Volume 17, Issue 5Author(s): J. Purvaneckas, J. Makevicius, A. Rimas, M. Sniureviciute
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: European Urology Supplements, Volume 17, Issue 5Author(s): K. Vaiciunas, J. Babakinas, K. Jokubonis, L. Jarusevicius, A. Inciura, E. Juozaityte, M. Jievaltas
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
More News: Brachytherapy | Study